Title:Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents
Volume: 22
Issue: 17
关键词:
COVID-19,刺突蛋白潜在冠状病毒靶点,基因改造,天然药物,交叉感染预防,ACE2。
摘要:
Background: By the end of 2019, the sudden outbreak of the novel coronavirus disease
(COVID-19) has become a global threat. It is called COVID-19 because it was caused by the novel
coronavirus (SARS-COV-2) in 2019. A total of 1.9 M deaths and 87.9 M cases have been reported
all over the world, where 49M cases have recovered so far. Scientists are working hard to find chemotherapeutics
and vaccines for COVID-19. Mutations in SARS-CoV-2 have been observed in a
combination of several hazardous stresses, making them more resistant and beneficial. So to break
down the viral system, the disease targets are examined.
Objective: In today's review, a comprehensive study of spike protein explains the main purpose of
the novel coronavirus and how to prevent the spread of the disease virus cross-transmission from infected
to a healthy person.
Methods: Covid-19 has already been declared a pandemic by the World Health Organization
(WHO) due to its result in causing death and severe illness globally. SARS-CoV-2 is highly contagious;
however, the intermediate host of the novel coronavirus is not clear. To explore the mechanisms
of disease, one of the viral targets, such as the spike protein that binds to human cells and
causes the disease by altering its genetic structure which is considered along with potential inhibitors.
Results: It has been shown that the interaction of receptor-binding domain (RBD) protein of
SARS- CoV-2 spike and the angiotensin-converting enzyme 2 (ACE2) host receptor and further replication
of coronavirus spike protein causes its invasion in the host cell. The human Lymphocyte
antigen 6 complex, Locus E (LY6E), inhibits the entry of CoV into host cells by interfering with
the human gene, inducing spike protein-mediated membrane fusion. Some natural formulations
have also been shown to prevent spike protein from binding to the host cell.
Conclusion: With the development of the LY6E gene activator that can inhibit spike protein-
ACE2-mediated membrane fusion, new opportunities for SARS-CoV-2 treatment may
emerge. Existing antiviral fusion inhibitors and natural compounds targeting spike resistance can
serve as a template for further SARS-CoV-2 drug formulation.